News & Updates

Exposure of senaparib, a highly potent poly-(ADP-ribose) polymerase 1/2 inhibitor and CYP3A4 substrate, is significantly increased when administered along with itraconazole and significantly decreased when taken together with rifampicin, reports a recent study involving healthy male volunteers (HMV) in China.

New drug applications approved by US FDA as of 01-15 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with ataluren improves ambulatory function, as assessed by the 6-minute walk distance (6MWD) test, among boys with nonsense mutation Duchenne muscular dystrophy (nmDMD), according to the subgroup analysis of Study 041 trial presented at AAN 2023.

Switching from other anti-VEGF* agents to brolucizumab only helps improve visual acuity and reduces disease activity in patients with neovascular (wet) age-related macular degeneration (nAMD)

Treatment with memantine significantly reduces hair pulling and skin-picking symptoms when compared with placebo, demonstrating relatively high efficacy and tolerability, reports a study.